Topline AstraZeneca on Tuesday announced its monoclonal antibody treatment for Covid-19 did not meet the primary goal of preventing symptoms in people who have been exposed to the coronavirus, denting hopes of a new therapeutic treatment for Covid-19 for unvaccinated people. AstraZeneca’s antibody treatment failed prevent symptoms among people who had been exposed to … [+] Covid-19. Getty Images Key Facts The antibody therapy, AZD7442, reduced the risk of developing symptomatic Covid-19 by only 33% among all exposed patients—including those who tested ne… Click below to read the full story from Forbes
Read More
AstraZeneca’s Covid-19 Antibody Treatment Failed To Prevent Symptoms In Exposed Individuals
